EE385 Cost per Outcome Analysis of Osimertinib and Atezolizumab for Adjuvant Non-Small Cell Lung Cancer EGFRm Stage II-IIIA in Two Years from Brazilian Private Health System Perspective
Abstract
Authors
L. Jabase P. Nazareth Aguiar F. Senra M. Massaoka